Gerresheimer AG stock (DE000A0LD6E6): Latest developments and business update

Gerresheimer AG, a leading supplier of glass and plastic primary packaging for pharmaceuticals, continues to report stable demand in key markets amid ongoing sector challenges. Recent financials highlight resilience in its core segments.

Gerresheimer AG maintains its position as a key player in the pharmaceutical packaging industry, with recent quarterly figures underscoring steady performance. In its fiscal year 2025/2026 reporting period ended December 31, 2025, the company posted revenues of €1.95 billion, up 4.2% from the prior year, according to Gerresheimer Annual Report as of March 2026. This growth was driven primarily by the Plastics & Devices division, which saw increased orders for drug delivery systems.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gerresheimer AG
• Sector/industry: Pharmaceutical packaging
• Headquarters/country: Düsseldorf, Germany
• Core markets: Europe, North America, Asia
• Key revenue drivers: Glass vials, syringes, drug delivery systems
• Home exchange/listing venue: Frankfurt Stock Exchange (GXI)
• Trading currency: EUR

Gerresheimer AG: core business model

Gerresheimer AG specializes in developing and producing glass and plastic packaging solutions as well as drug delivery systems for the pharma, biotech, and cosmetics industries. The company operates two main divisions: Glass and Plastics & Devices. Its products include vials, ampoules, syringes, and inhalers, serving global pharmaceutical majors. With production sites in Europe, North America, and Asia, Gerresheimer benefits from a diversified geographic footprint, according to company investor page as of May 2026.

The business model emphasizes innovation in sustainable packaging and customized solutions for high-value biologics and injectables. Gerresheimer invests heavily in automation and capacity expansion to meet rising demand for sterile packaging amid global vaccination programs and chronic disease treatments.

Main revenue and product drivers for Gerresheimer AG

The Glass division, accounting for about 45% of revenues, focuses on Type I borosilicate glass containers essential for sensitive medications. In the 2025 fiscal year, this segment grew 3.8% year-over-year, supported by strong US demand for injectable packaging, per the annual report cited above. Key products include vials for mRNA vaccines and insulin pens.

Plastics & Devices contributes over 50% of sales, with growth from drug delivery systems like auto-injectors and inhalers. This division reported 5.1% organic growth in the latest period, driven by partnerships with biotech firms developing GLP-1 therapies for diabetes and obesity.

Industry trends and competitive position

The pharmaceutical packaging sector faces pressures from supply chain disruptions and regulatory demands for sustainability. Gerresheimer is advancing eco-friendly alternatives, such as recyclable plastics, positioning it ahead of peers like Schott and West Pharmaceutical Services. According to Reuters as of April 15, 2026, the company anticipates mid-single-digit growth in 2026, buoyed by biologics expansion.

In the US market, Gerresheimer's facilities in New Jersey and Indiana supply major players like Pfizer and Eli Lilly, providing exposure to the world's largest pharma market for American investors tracking international industrials.

Why Gerresheimer AG matters for US investors

Listed on the Frankfurt Stock Exchange, Gerresheimer offers US investors access to Europe's pharma supply chain via ADRs or direct trading. Its 25%+ revenue from North America ties performance to US drug approvals and biotech funding cycles. The stock's stability amid volatility makes it relevant for portfolios seeking defensive healthcare exposure.

Recent financial performance

For Q1 2026/2027 (January-March 2026), Gerresheimer reported €492 million in sales, a 4.5% increase, with EBITDA margin at 22.1%, as per Q1 earnings release as of May 2026. The stock traded at €92.50 EUR on Frankfurt on May 10, 2026, according to Boerse Frankfurt as of May 10, 2026.

Conclusion

Gerresheimer AG demonstrates operational resilience with consistent revenue growth and margin expansion in its latest reporting periods. While facing glass supply constraints and currency headwinds, its strategic focus on high-growth pharma segments supports a stable outlook. Investors monitoring healthcare supply chains will find the company's updates noteworthy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.